A PHASE 1B, OPEN-LABEL, EXPLORATORY STUDY EVALUATING THE EFFECTS OF INHALED EPINEPHRINE IN INDIVIDUALS EXPERIENCING SYSTEMIC ALLERGIC REACTIONS DURING ALLERGY TESTING, IMMUNOTHERAPY OR ORAL CHALLENGES

Registry ID

GHL-102

Source registry

HEALTH_CANADA

Status

Ongoing

Phase

PHASE1

Study type

INTERVENTIONAL

Sponsor

KOKUA PHARMA INC.

Start date

2026-01-27

Last update

2025-05-28

Conditions

• ALLERGIES

Related clinical trials

• AN OPEN-LABEL, MULTI-CENTER PROTOCOL FOR PATIENTS WHO HAVE COMPLETED A PREVIOUS NOVARTIS SPONSORED REMIBRUTINIB STUDY AND ARE JUDGED BY THE INVESTIGATOR TO BENEFIT FROM CONTINUED TREATMENT WITH REMIBRUTINIB
• PREMED-F1: FEASIBILITY OF A RANDOMIZED CONTROLLED TRIAL TO COMPARE THE USE OF CETIRIZINE AS A REPLACEMENT FOR DYPHENHYDRAMINE TO PREVENT REACTIONS LINKED TO PACLITAXEL PERFUSION

View on source registry